Synthesis and evaluation of antiproliferative activity of a geldanamycin–Herceptin™ immunoconjugate
- 1 May 2000
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (10) , 1025-1028
- https://doi.org/10.1016/s0960-894x(00)00155-4
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- ERBB2 oncogene in human breast cancer and its clinical significanceEuropean Journal Of Cancer, 1998
- Preclinical and clinical study of HER-2/neu-targeting cancer gene therapyAdvanced Drug Delivery Reviews, 1998
- Clinical experience with CD64-directed immunotherapy. An overviewCancer Immunology, Immunotherapy, 1997
- Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatmentCancer Immunology, Immunotherapy, 1997
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Requirement for neuregulin receptor erbB2 in neural and cardiac developmentNature, 1995
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Monoclonal antibody-based therapies of leukemia and lymphomaBlood, 1992
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975